Trinity Biotech (NASDAQ:TRIB) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Rating) in a note issued to investors on Wednesday. The brokerage set a “buy” rating on the stock.

Trinity Biotech Stock Down 4.2 %

Trinity Biotech stock opened at $0.92 on Wednesday. The company has a 50 day moving average of $0.95 and a 200-day moving average of $1.07. The company has a quick ratio of 1.39, a current ratio of 2.69 and a debt-to-equity ratio of 8.70. Trinity Biotech has a twelve month low of $0.80 and a twelve month high of $1.50. The stock has a market capitalization of $35.06 million, a PE ratio of -0.71 and a beta of 1.41.

Trinity Biotech (NASDAQ:TRIB – Get Rating) last announced its earnings results on Thursday, March 23rd. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.12). Trinity Biotech had a negative return on equity of 724.07% and a negative net margin of 54.84%. The company had revenue of $18.04 million during the quarter, compared to analyst estimates of $18.00 million. On average, equities research analysts anticipate that Trinity Biotech will post -0.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Trinity Biotech

Institutional investors have recently bought and sold shares of the company. Atria Wealth Solutions Inc. bought a new position in shares of Trinity Biotech during the 1st quarter worth approximately $27,000. Virtu Financial LLC bought a new position in Trinity Biotech in the first quarter valued at approximately $40,000. Whitefort Capital Management LP grew its stake in Trinity Biotech by 1,067.8% in the first quarter. Whitefort Capital Management LP now owns 409,517 shares of the company’s stock valued at $434,000 after purchasing an additional 374,449 shares in the last quarter. Hunter Associates Investment Management LLC increased its position in shares of Trinity Biotech by 1.5% during the 4th quarter. Hunter Associates Investment Management LLC now owns 1,823,633 shares of the company’s stock worth $1,809,000 after purchasing an additional 26,443 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Trinity Biotech by 2.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,503,336 shares of the company’s stock valued at $1,842,000 after buying an additional 34,900 shares during the last quarter. Institutional investors own 18.41% of the company’s stock.

Trinity Biotech Company Profile

(Get Rating)

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. It operates through the Americas and Rest of World geographical segments. The company was founded by Ronan O’Caoimh and Denis R.